<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>4</IssueIDStart>
          <IssueIDEnd>4</IssueIDEnd>
          <IssueArticleCount>15</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>12</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2006</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art2">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>74786</ArticleID>
            <ArticleDOI>10.1208/aapsj070477</ArticleDOI>
            <ArticleSequenceNumber>2</ArticleSequenceNumber>
            <ArticleTitle Language="En">Equivalence studies for complex active ingredients and dosage forms</ArticleTitle>
            <ArticleFirstPage>E786</ArticleFirstPage>
            <ArticleLastPage>E812</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2004</Year>
                <Month>7</Month>
                <Day>15</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>10</Month>
                <Day>14</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>4</IssueIDStart>
              <IssueIDEnd>4</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Lokesh</GivenName>
                  <FamilyName>Bhattycharyya</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Roger</GivenName>
                  <FamilyName>Dabbah</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Walter</GivenName>
                  <FamilyName>Hauck</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Eric</GivenName>
                  <FamilyName>Sheinin</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Lynn</GivenName>
                  <FamilyName>Yeoman</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Roger</GivenName>
                  <FamilyName>Williams</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(301) 816-8300</Phone>
                  <Fax>(301) 816-8299</Fax>
                  <Email>rlw@usp.org</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>United States Pharmacopeia</OrgName>
                <OrgAddress>
                  <Street>12601 Twinbrook Parkway</Street>
                  <Postcode>20852-1790</Postcode>
                  <City>Rockville</City>
                  <State>MD</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Biostatistics Section</OrgDivision>
                <OrgName>Thomas Jefferson University</OrgName>
                <OrgAddress>
                  <Postcode>19107</Postcode>
                  <City>Philadelphia</City>
                  <State>PA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgName>Baylor College of Medicine</OrgName>
                <OrgAddress>
                  <Postcode>77030</Postcode>
                  <City>Houston</City>
                  <State>TX</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>This article examines the United States Pharmacopeia (USP) and its role in assessing the equivalence and inequivalence of biological and biotechnological drug substances and products—a role USP has played since its founding in 1820. A public monograph in the<Emphasis Type="Italic">United States Pharmacopeia-National Formulary</Emphasis> helps practitioners and other interested parties understand how an article’s strenght, quality, and purity should be controlled. Such a monograph is a standard to which all manufactured ingredients and products should conform, and it is a starting point for subsequent-entry manufactures, recognizing that substantial additional one-time characterization studies may be needed to document equivalence. Review of these studies is the province of the regulatory agency, but compendial tests can provide clarity and guidance in the process.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>US Pharmacopeia</Keyword>
              <Keyword>biological or biotechnological drug</Keyword>
              <Keyword>equivalence</Keyword>
              <Keyword>generic biologics</Keyword>
              <Keyword>complex active ingredient</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: November 17, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_74786.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibUnstructured>USP. About USP—an overview. Available at: www.usp.org/aboutUSP/.Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>Board of Trustees, United States Pharmacopeial Convention</InstitutionalAuthorName>
                  <Year>2000</Year>
                  <BookTitle>United States Pharmacopeial Convention Quinquennial Meeting 2000 Proceedings</BookTitle>
                  <PublisherName>United States Pharmacopeial Convention</PublisherName>
                  <PublisherLocation>Rockville, Maryland</PublisherLocation>
                  <FirstPage>400</FirstPage>
                  <LastPage>400</LastPage>
                </BibBook>
                <BibUnstructured>Board of Trustees, United States Pharmacopeial Convention.<Emphasis Type="Italic">United States Pharmacopeial Convention Quinquennial Meeting 2000 Proceedings</Emphasis>. Rockville, Maryland: United States Pharmacopeial Convention; 2000:400.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibUnstructured>USP. Biological and Biotechnological Drug Substances and Products Workbook; November 18–21, 2003; Crystal City, VA. 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>World Health Organization</InstitutionalAuthorName>
                  <Year>2000</Year>
                  <BookTitle>Consultation on International Biological Standards for In Vitro Diagnostic Procedures, Blood Safety, and Clinical Technology</BookTitle>
                  <PublisherName>World Health Organization</PublisherName>
                  <PublisherLocation>Geneva, Switzerland</PublisherLocation>
                </BibBook>
                <BibUnstructured>World Health Organization.<Emphasis Type="Italic">Consultation on International Biological Standards for In Vitro Diagnostic Procedures, Blood Safety, and Clinical Technology</Emphasis>. Geneva, Switzerland: World Health Organization; 2000.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>Federal Food, Drug, and Cosmetics Act, 21<Emphasis Type="Italic">USC</Emphasis> § 321(g).</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibUnstructured>United States Public Health Service Act, 42<Emphasis Type="Italic">USC</Emphasis> § 262(i).</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>National Biological Standards Board</InstitutionalAuthorName>
                  <Year>1975</Year>
                  <BookTitle>Biological Standards Act</BookTitle>
                  <PublisherName>The Stationer’s Office</PublisherName>
                  <PublisherLocation>London, UK</PublisherLocation>
                </BibBook>
                <BibUnstructured>National Biological Standards Board.<Emphasis Type="Italic">Biological Standards Act</Emphasis>. London, UK: The Stationer’s Office; 1975.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibUnstructured>The<Emphasis Type="Italic">BioPharm</Emphasis> Lexicon.<Emphasis Type="Italic">BioPharm</Emphasis>. 2002;15(suppl).</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibUnstructured>Office of the Special Assistant for Gulf War Illnesses. Observations TABA—acronyms, abbreviations, and glossary. GulfLINK Web site. Available at: www.gulflink.osd.mil/va/va_taba.htm. Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>
                  <Emphasis Type="Italic">The Pharmacopoeia of the United States of America</Emphasis>. Boston, MA: Fells and Lilly, 1820.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibChapter>
                  <InstitutionalAuthorName>WHO Expert Committee on Specifications for Pharmaceutical Preparations</InstitutionalAuthorName>
                  <Year>1999</Year>
                  <NoChapterTitle/>
                  <BookTitle>Annex 11: Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products</BookTitle>
                  <SeriesTitle Language="En">Thirty-Fourth Report</SeriesTitle>
                  <PublisherName>World Health Organization</PublisherName>
                  <PublisherLocation>Geneva, Switzerland</PublisherLocation>
                </BibChapter>
                <BibUnstructured>WHO Expert Committee on Specifications for Pharmaceutical Preparations, ed. Annex 11: Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products. In:<Emphasis Type="Italic">Thirty-Fourth Report</Emphasis>. Geneva, Switzerland: World Health Organization; 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RL</Initials>
                    <FamilyName>Williams</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ML</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WW</Initials>
                    <FamilyName>Hauck</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Equivalence approaches</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>72</VolumeID>
                  <FirstPage>229</FirstPage>
                  <LastPage>237</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12235443</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1067/mcp.2002.126705</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Williams RL, Chen ML, Hauck WW. Equivalence approaches.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2002;72:229–237.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibUnstructured>Food and Drug Administration Modernization Act of 1997. 21<Emphasis Type="Italic">USC</Emphasis> 301 § 116.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibUnstructured>ICH. International Conference on Harmonization Q5E guideline: comparability of biotechnological/biological products subject to changes in their manufacturing process. Available at: www.ich.org/cache/compo/276-254-1.html. Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibUnstructured>FDA Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for industry: premarketing risk assessment. Available at: www.fda.gov/cber/gdlns/premarkrisk.pdf. Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibUnstructured>FDA Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for industry: development and use of risk-minimization action plans. Available at: www.fda.gov/cber/gdlns/riskminim.pdf. Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibUnstructured>Task Force on Risk Managment. Managing the risks from medical product use: creating a risk management framework. Available at: http://www.fda.gov/oc/tfrm/riskmanagement.html. Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>Committee for Proprietary Medicinal Products</InstitutionalAuthorName>
                  <Year>2003</Year>
                  <BookTitle>Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues</BookTitle>
                  <PublisherName>European Medicines Evaluation Agency</PublisherName>
                  <PublisherLocation>London, England</PublisherLocation>
                </BibBook>
                <BibUnstructured>Committee for Proprietary Medicinal Products.<Emphasis Type="Italic">Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues</Emphasis>. London, England: European Medicines Evaluation Agency; 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Schuirmann</FamilyName>
                  </BibAuthorName>
                  <Year>1987</Year>
                  <ArticleTitle Language="En">A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability</ArticleTitle>
                  <JournalTitle>J Pharmacokinet Biopharm</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>657</FirstPage>
                  <LastPage>680</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3450848</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF01068419</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:BieB3s%2FitVM%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1987;15:657–680.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibUnstructured>FDA. Guidance for industry: statistical approaches to estabilishing bioequivalence. Available at: www.fda.gov/cder/guidance/3616fnl.htm. Accessed October 10, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibUnstructured>USP Open Presentations of Violand B, Workman W, Hardy M, Mulkerrin M, Davis G, Mire-Sluis A, Cavagnaro J, Rogge M, Balthasar J, Swanson S, Hauck W. Conference on Biological and Biotechnological Drug Substances and Products. November 18–21, 2003; Arlington, VA.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AR</Initials>
                    <FamilyName>Mire-Sluis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RG</Initials>
                    <FamilyName>Das</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Padilla</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis, and as therapeutic agents</ArticleTitle>
                  <JournalTitle>J Immunol Methods</JournalTitle>
                  <VolumeID>216</VolumeID>
                  <FirstPage>103</FirstPage>
                  <LastPage>116</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9760218</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0022-1759(98)00073-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXls1Oqsr0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mire-Sluis AR, Das RG, Padilla A. WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis, and as therapeutic agents.<Emphasis Type="Italic">J Immunol Methods</Emphasis>. 1998;216:103–116.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AR</Initials>
                    <FamilyName>Mire-Sluis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Padilla</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RG</Initials>
                    <FamilyName>Das</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Biological standardization of cytokines and growth factors</ArticleTitle>
                  <JournalTitle>Dev Biol Stand</JournalTitle>
                  <VolumeID>97</VolumeID>
                  <FirstPage>171</FirstPage>
                  <LastPage>176</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10463542</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1MzptFWrsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mire-Sluis AR, Padilla A, Das RG. Biological standardization of cytokines and growth factors.<Emphasis Type="Italic">Dev Biol Stand</Emphasis>. 1999;97:171–176.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WW</Initials>
                    <FamilyName>Hauck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RC</Initials>
                    <FamilyName>Capen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Callahan</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Assessing parallelism prior to determining relative potency</ArticleTitle>
                  <JournalTitle>PDA J Pharm Sci Technol</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>127</FirstPage>
                  <LastPage>137</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15971545</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hauck WW, Capen RC, Callahan JD, et al. Assessing parallelism prior to determining relative potency.<Emphasis Type="Italic">PDA J Pharm Sci Technol</Emphasis>. 2005;59:127–137.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibUnstructured>ICH. E10 guideline, Choice of control group in clinical trials. Available at: www.ich.org/MediaServer.jser?@_ID=486&amp;@_MODE=GLB. Accessed October 11, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Copmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Davis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Garnick</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">One product, one process, one set of specifications</ArticleTitle>
                  <JournalTitle>Pharm Technol</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>26</FirstPage>
                  <LastPage>36</LastPage>
                </BibArticle>
                <BibUnstructured>Copmann T, Davis G, Garnick R, et al. One product, one process, one set of specifications.<Emphasis Type="Italic">Pharm Technol</Emphasis>. 2001;25:26–36.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibUnstructured>ICH. Q6B Guideline, Specifications: test procedures and acceptance criteria for biotechnological/biological products. Available at: www.ich.org/MediaServer.jser?@_ID=432&amp;@_MODE=GLB. Accessed October 11, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibUnstructured>Anon. Clearer paradigm sought for biopharmaceutical specifications:<Emphasis Type="Italic">Gold Sheet.</Emphasis> 2004;38:1–32.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
